Therapeutic efficacy and safety of telmisartan in patients with non-alcoholic fatty liver disease (NAFLD) and hypertension: exploratory research

Therapeutic efficacy and safety of telmisartan in patients with non-alcoholic fatty liver disease (NAFLD) and hypertension: exploratory research - Efficacy and safety of telmisartan in patients with NAFLD and hypertension

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020537

Enrollment

Registered

2016-01-12

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease and hypertension

Interventions

telmisartan (20 to 80 mg daily)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) ALT >= 30 IU/L without excess alcohol consumption (2) Controlled attenuation parameter (CAP)>= 250 dB/m (3) Clinic blood pressure >= 130/85 mmHg (4) Written informed consent

Exclusion criteria

Exclusion criteria: (1) Treatment histody of ARB, ACE inhibitor, renin inhibitor, or thiazolidine (2) History of hepatic disease, such as chronic hepatitis C or concurrent active hepatitis B (serum positive for hepatitis B surface antigen), autoimmune hepatitis, or primary biliary cirrhosis (PBC) (3) Secondary hypertension (4) History of allergy for telmisartan (5) Pregnancy or lactation in women (6) Inadequacy for this therapy

Design outcomes

Primary

Measure	Time frame
The change in the value of liver fibrosis marker between baseline and after 12 months of treatment	—

Countries

Japan

Contacts

Public ContactMotohiro Shimizu

Kyushu University Hospital Department of General Internal Medicine

smotohir@gim.med.kyushu-u.ac.jp092-642-5909

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026